Sematrinity for Weight Loss in India: Does It Work?
Sematrinity (Sun Pharma generic semaglutide) is now available in India post-patent expiry. Here is what the evidence says about weight loss results, dosing, and pricing.
Generic semaglutide arrived in India on March 20, 2026. Among the 50+ brands entering the market on patent expiry day, Sun Pharma's Sematrinity is the headline launch - and for anyone with obesity or type 2 diabetes in India, the weight loss question is the most important one to answer clearly.
Does it work? Here is the honest picture.
What is Sematrinity?
Sematrinity is Sun Pharma's generic version of semaglutide - the active molecule in Ozempic and Wegovy. It is a once-weekly subcutaneous injection that works as a GLP-1 receptor agonist: mimicking the gut hormone GLP-1 to suppress appetite, slow gastric emptying, and improve insulin response.
It became available post-patent expiry on March 20, 2026, with DCGI approval secured in December 2025.
Sun Pharma has separated its semaglutide brands:
- Sematrinity - for type 2 diabetes (primary indication, up to 1 mg dose)
- Noveltreat - for chronic obesity management (up to 2.4 mg, matching Wegovy dosing)
If your primary goal is weight loss rather than diabetes management, Noveltreat is the relevant Sun Pharma brand to discuss with your doctor.
How does it promote weight loss?
Semaglutide produces weight loss through several mechanisms:
Appetite suppression. GLP-1 receptors in the hypothalamus (brain's appetite centre) receive signals that reduce hunger and food cravings. Most people experience a significant reduction in appetite, particularly for high-calorie foods.
Slower gastric emptying. Food stays in the stomach longer, extending the sensation of fullness after smaller meals.
Reduced calorie intake. The combined effect is that patients naturally eat less - typically 30–40% fewer calories - without deliberate restriction.
Improved insulin sensitivity. This reduces metabolic dysfunction that contributes to weight gain in people with type 2 diabetes or prediabetes.
What the trials show: the key numbers
Semaglutide's weight loss evidence is extensive. The STEP (Semaglutide Treatment Effect in People with Obesity) trial program is the most relevant:
STEP 1 - Obesity without diabetes
- 68 weeks, 1,961 adults
- Semaglutide 2.4 mg: average 14.9% weight loss (~15.3 kg)
- Placebo: 2.4% weight loss
- 86% of participants lost at least 5% of body weight vs 32% on placebo
STEP 2 - Obesity + type 2 diabetes
- 68 weeks
- Semaglutide 2.4 mg: 9.6% average weight loss
- Placebo: 3.4%
Long-term data
Studies following participants for up to 4 years show maintained weight loss with continued use. Stopping the medication typically leads to weight regain - semaglutide treats obesity as an ongoing condition, not a one-time intervention.
Sematrinity vs Ozempic: is it truly the same?
Generic medicines contain the same active ingredient at the same dose. Indian regulatory approval through the DCGI requires demonstration of bioequivalence - meaning the body absorbs and uses the generic at a comparable rate and extent to the original.
Sun Pharma's Phase III clinical data in India additionally confirmed safety and efficacy in Indian adult populations.
In practice: Sematrinity contains the same semaglutide molecule as Ozempic, at the same dose, with the same weekly injection schedule, producing comparable clinical effects.
Pricing breakdown
| Brand | Monthly cost (approx.) |
|---|---|
| Ozempic (imported, 1 mg) | ₹12,000–₹18,000 |
| Sematrinity 0.5–1 mg | ₹4,000–₹8,000 |
| Noveltreat (weight loss, 2.4 mg) | ₹5,000–₹9,000 (estimated) |
| Other generics (Semaglyn, etc.) | ₹3,500–₹7,000 |
With competition from 50+ generics, prices are expected to fall further through 2026 as supply stabilises.
Who is it for?
Sematrinity (diabetes indication) is appropriate for adults with:
- Type 2 diabetes not adequately controlled by oral medication alone
- Overweight or obesity alongside their diabetes diagnosis
Noveltreat (weight management indication) is appropriate for adults with:
- Obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, without a diabetes diagnosis requirement
- Those who previously could not afford imported semaglutide for weight management
Side effects to expect
Side effects are identical to those of Ozempic and Wegovy - because the molecule is identical:
Very common (>10%):
- Nausea - typically peaks in the first 4–8 weeks and improves significantly
- Diarrhea or constipation
Common (1–10%):
- Vomiting
- Abdominal discomfort
- Fatigue, dizziness in early weeks
The standard GLP-1 class warnings apply:
- Thyroid C-cell tumours: contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Pancreatitis: seek medical attention for severe abdominal pain
Practical tips for Indian patients
Start low, go slow. Begin at 0.25 mg for the first 4 weeks. Rushing the titration increases GI side effects significantly.
Protein first. Indian diets can be lower in protein than optimal during rapid weight loss. Prioritise dal, paneer, Greek yoghurt, eggs, and legumes to maintain muscle and reduce hair thinning risk.
Track your doses. Missing a weekly injection or losing track of where you are in the titration is common without a system. WeightEasy supports semaglutide tracking for Indian users.
Buy from licensed sources only. Counterfeit GLP-1 pens are a documented issue. Purchase only from registered pharmacies - 1mg, Netmeds, PharmEasy, or directly from hospital pharmacies.
Combine with lifestyle changes. The trial data showing 15% weight loss was achieved with a 500-calorie deficit diet and 150 minutes of weekly exercise. Medication alone, without lifestyle change, produces significantly smaller results.
What does this mean for India's obesity market?
India has approximately 77 million people with type 2 diabetes and rising urban obesity rates exceeding 20% in major cities. Until today, GLP-1 therapy was largely inaccessible due to cost - Ozempic at ₹12,000–₹18,000 per month is beyond reach for most.
Generic semaglutide at ₹3,500–₹8,000 changes the calculation fundamentally. Analysts project the Indian obesity drug market - currently approximately ₹1,400 crore - could double within 2–3 years driven by generic GLP-1 adoption.
Final takeaway
Sematrinity contains the same semaglutide as Ozempic, approved in India from March 20, 2026, at approximately half the cost of imported options. Clinical evidence for semaglutide is extensive - average 15% body weight loss over 68 weeks in people with obesity. For diabetes management, glycaemic benefits are comparable to the best available options. If you have type 2 diabetes or obesity in India, this is now a realistic and accessible conversation to have with your endocrinologist.
Always consult your healthcare provider before starting any medication. Results vary by individual.
Sources
- Sun Pharmaceutical Industries Ltd. - Sematrinity and Noveltreat product communications, March 2026
- DCGI approval for Sun Pharma semaglutide: December 2025
- STEP 1 trial: Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002
- STEP 2 trial: Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes. Lancet. 2021;397(10278):971–984
- Ozempic prescribing information - Novo Nordisk
FAQ
How much weight loss with Sematrinity?
Clinical trials on semaglutide - the active ingredient in Sematrinity - show an average of approximately 15% body weight loss over 68 weeks in people with obesity. In diabetes trials, weight loss averages around 6–9% alongside blood sugar improvement.
Is Sematrinity the same as Ozempic for weight loss?
Yes - Sematrinity contains the same active molecule (semaglutide) as Ozempic. Generic medicines must contain the same active ingredient at the same dose and must demonstrate bioequivalence (same absorption and effect) to the original.
Is Sematrinity safe long-term?
Semaglutide's long-term safety profile is well established through four-plus years of clinical trial data and several years of real-world use globally. GI side effects (nausea, diarrhea) are common initially but typically reduce within weeks. The standard class warnings apply - including thyroid tumour risk and pancreatitis risk, which should be discussed with your doctor.
Where can I get Sematrinity in Lucknow or Delhi?
Sematrinity became available at major pharmacies and chains across metro cities from March 20, 2026. Check platforms like 1mg for your city. A prescription from an endocrinologist or diabetologist is required.
Sematrinity vs Noveltreat - what is the difference?
Both are from Sun Pharma and both contain semaglutide. Sematrinity is positioned for type 2 diabetes management (up to 1 mg dose). Noveltreat is Sun Pharma's brand for chronic weight management in obesity, at the higher 2.4 mg dose used in the STEP obesity trials.